Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MRNA vs REGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REGN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)

REGN Overall Winner 6-Pillar Tally: MRNA 1 – 5 REGN Matrix Metrics: MRNA 0 – 10 REGN

As of Nov 20, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas REGN carries 46.0/100 (HOLD) at $920.69 (14.8x Forward P/E, 30.4% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRNA vs REGN
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89
REGN NASDAQ Head-to-Head Winner
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$920.69
-0.29% 1D
Market Cap $95.5B
TTM Revenue $16.9B
Forward P/E 14.8x
Beta / 30D Vol 0.30β · 55% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 29.0 Fund 49.0 Flow 69.0 Mom 56.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.9% over 20 days), RSI 57
RSI-14: 57.2 · SMA20: $912.90 · SMA50: $829.76

6-Pillar Scorecard Institutional Category Breakdown (MRNA 1 – 5 REGN)

Columns: Metric · MRNA · REGN
1. Valuation Multiples REGN
Forward P/E 23.0x 14.8x
Trailing P/E 23.0x 20.4x
PEG Ratio N/M 1.15x
EV / Revenue 33.1x 5.6x
2. Growth & Scale REGN
Revenue Growth (YoY) +29.2% +36.3%
Earnings Growth (YoY) -85.1% +35.5%
TTM Revenue (USD) $2.52B $16.9B
Market Cap $80.7B $95.5B
3. Profitability & Quality REGN
Gross Margin -42.0% 46.7%
Operating Margin -80.8% 30.4%
Net Profit Margin -110.5% 28.5%
Return on Equity (ROE) -34.5% 14.9%
4. Balance Sheet & Cash Flow REGN
Cash Generation (TTM) -$2.04B $3.63B
Cash Flow Margin -81.0% 21.5%
Net Cash / Leverage $3.03B Net Debt (0.62x D/E) $952M Net Cash
Dividend Yield None (0.00%) 0.39%
5. Options & Positioning REGN
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 89.6% (52nd %ile) 39.4% (6th %ile)
Put/Call OI Skew 1.05x (Balanced) 0.58x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 38.8% of Rev ($980M) 16.3% of Rev ($2.75B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRNA (0) vs REGN (10)
Institutional Metric MRNA REGN Criterion Row Edge
Market Capitalization
Scale
$80.7B $95.5B Larger Scale REGN
Trailing P/E Ratio
Valuation
23.0x 20.4x Lower Multiple REGN
Forward P/E Ratio
Valuation
23.0x 14.8x Lower Multiple REGN
Revenue Growth (YoY)
Growth
+29.2% +36.3% Higher Growth REGN
Operating Margin (TTM)
Profitability
-80.8% 30.4% Higher Margin REGN
Net Profit Margin
Profitability
-110.5% 28.5% Higher Margin REGN
Return on Equity (ROE)
Capital Efficiency
-34.5% 14.9% Higher ROE REGN
52-Week Range Position
Momentum
67% ($22–$281) 82% ($592–$992) Stronger Trend REGN
Beta / 30D Volatility
Risk Regime
2.23β · 78% Vol 0.30β · 55% Vol Lower Realized Risk REGN
Unified Institutional Score
Composite Signal
40.3 / 100 (SELL) 46.0 / 100 (HOLD) Higher Composite REGN
Trailing 12M Revenue (USD)
Operating Scale
$2.52B $16.9B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.0% 46.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 33.1x EV/Rev 1.15x PEG · 5.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.04B ($3.03B Net Debt (0.62x D/E)) $3.63B ($952M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REGN +16.17 pp
MRNA: -3.77% · REGN: +12.4%
3M Horizon MRNA +29.27 pp
MRNA: +40.4% · REGN: +11.13%
6M Horizon MRNA +271.85 pp
MRNA: +315.96% · REGN: +44.11%
1Y Horizon MRNA +675.44 pp
MRNA: +706.45% · REGN: +31.01%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MRNA Revenue REGN Revenue MRNA Op. Margin REGN Op. Margin Margin Leader
FY2018 $140M $5.15B -306.0% 49.3% REGN
FY2019 $60M $6.56B -906.8% 33.7% REGN
FY2020 $800M $8.50B -95.0% 42.1% REGN
FY2021 $18.5B $16.1B 72.0% 55.7% MRNA
FY2022 $19.3B $12.2B 48.9% 38.9% MRNA
FY2023 $6.85B $13.1B -61.9% 30.9% REGN
FY2024 $3.24B $14.2B -121.9% 28.1% REGN
FY2025 $1.94B $14.3B -158.1% 24.9% REGN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
REGN CONSOLIDATION
56d in phase · OBV DISTRIBUTION
Current IV 39.4%
IV Percentile 6th %ile
Put/Call OI Skew 0.58x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact REGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA vs. REGN: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of MRNA ($21,527) vs. REGN ($95,240) against risk-defined 5-day vertical and put-wall option structures.

MRNA Spot $215.27 · IV 83.7%
MRNA Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
REGN Spot $952.40 · IV 33.5%
REGN Options Simulator →
5-DAY BULLISH SWING Liq C

Dec 18 $950 / $1,000 Bull Call Spread

Buy 1x $950C · Sell 1x $1,000C · 31d

Net Entry $2,387 Debit
T+5d @ +5% Move +$891 (+37%)
Max Risk / Buffer $2,387 Capped
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $880 / $820 Bull Put Spread

Sell 1x $880P · Buy 1x $820P · 59d

Net Entry $1,367 Credit
Max Credit / Yield +$1,367 (+29.5% RoM)
Max Risk / Buffer -9.0% Cushion ($4,633 Mgn)
5d Edge & Liquidity 75% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics
REGN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $95.5B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment 16.3% of Rev ($2.75B)
90D Engineering Disclosures 0 Published

Investor FAQ MRNA vs REGN Key Questions & Quantitative Answers

As of Nov 20, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas REGN carries 46.0/100 (HOLD) at $920.69 (14.8x Forward P/E, 30.4% operating margin). Technically, MRNA sits in a Neutral phase (RSI 41.5, CONSOLIDATION options structure) and REGN sits in a Markup phase (RSI 57.2, CONSOLIDATION options structure).

REGN leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with REGN at +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MRNA cumulative revenue shifted +1285.7% while REGN shifted +178.4%. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus 16.3% of Rev ($2.75B) (0 disclosures) for REGN.

REGN screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas REGN trades at 14.8x Forward P/E, 20.4x Trailing P/E, 1.15x PEG, and 5.6x EV/Revenue (21.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus REGN (14.9% ROE) capital efficiency.

In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, REGN carries 39.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.58x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.30β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.